Novel Nasal Formulation and Delivery Summit

Not only has the pandemic fuelled interest in new modalities research, but it has also triggered a renaissance of formulation approaches amongst biopharma to bring new wave of drug substances and therapeutics to life. Impel Pharmaceuticals, SciSparc Odyssey Health, and Intravacc are amongst the pioneers that stole the spotlight with their intranasal formulation delivery entering clinical trials.

With the advent of mature particle characterization and engineering, improved biophysiological understanding, and emphasis of patient centricity, intranasal and inhaled formatted drug products will offer unprecedented opportunities with widened therapeutic window for patients, beyond vaccine and pulmonary indications, with direct access to CNS.

In collaboration with Cipla, Impel Pharmaceuticals, Neurelis and SaNOtize, the Novel Nasal Formulation and Delivery Summit will be premier in San Diego, uniting 60+ senior leaders from biopharma to:

- Share approaches to formulate a novel nasal drug product with stability beyond small molecules and cross-learning from inhalations
- Overcome bioavailability and permeability challenges for rapid absorption by targeting olfactory system and targeted delivery to destined cells and organs
- Deeper our biophysiological and biodistribution understanding to reduce adsorption rate and immune response
- Widen the therapeutic window with patient centricity for your pipeline progression through this unique route of administration and enhance patient adherence
- Ensure a compatible, cost-effective device for filing and speed-to-market

Join us in San Diego in May to meet 60+ senior scientific leaders to improve your formulated products!

Early booking and group discounts available - visit the website for more information.

Speakers: Robert Thorne, Denali Fellow, Adjunct Associate, Professor Denali Therapeutics, University of Minnesota, Chris Miller, Chief Scientific Officer, SaNOtize, Whitney Binder, Principal Scientist, Genentech Inc, Krishna Subramanian, Vice President, Head of Non Clinical Development and Translational Science, Seelos Therapeutics Inc., Ross Walenga, Chemical Engineer, Office of Generic Drugs, FDA, Stephen Shrewsbury, Chief Medical Officer, Impel Pharmaceuticals, Jacob Vandlandingham, Head of Drug Development, Odyssey Group, Kapileswar Swain, Vice President and Head Respiratory New Technology, Cipla, Stuart Madden, Chief Scientific Officer, Neurelis, Inc, Andrew Martin, Associate Professor, Mechanical Engineering, University of Alberta, Ke Cheng, Professor of Biomedical Engineering, UNC-Chapel Hill, Debanjan Das, Senior Associate Director and Science Fellow - Global Research and Development, Bayer U.S. LLC, Anna Blakney, Assistant Professor, University of British Columbia, Senior Representative, Drug Product Reviewer, Office of New Drug Products, FDA, Tian Wu, Head of Pharmaceutics, AffaMed Therapeutics, Senior Representative, Supervisory Pharmacologist, Office of Neuroscience, FDA

Others Details

Brochure: https://go.evvnt.com/1544713-3?pid=6581